Details

Autor(en) / Beteiligte

• Tatekawa, Hiroyuki
• Hagiwara, Akifumi
• Uetani, Hiroyuki
• Yao, Jingwen
• Oughourlian, Talia C.
• Bahri, Shadfar
• Wang, Chencai
• Raymond, Catalina
• Lai, Albert
• Cloughesy, Timothy F.
• Nghiemphu, Phioanh L.
• Liau, Linda M.
• Pope, Whitney B.
• Salamon, Noriko
• Ellingson, Benjamin M.

Titel

Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas

Ist Teil von

• Journal of neuro-oncology, 2020-09, Vol.149 (2), p.337-346

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2020

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Purpose To assess whether hypermetabolically-defined regions of interest (ROIs) on 3,4-dihydroxy-6-[18F]-fluoro- l -phenylalanine (FDOPA) positron emission tomography (PET) could be used to evaluate physiological features and whether there are measurable differences between molecular subtypes and tumor grades. Methods Sixty-eight treatment-naïve glioma patients who underwent FDOPA PET and magnetic resonance imaging (MRI) were retrospectively included. Fluid-attenuated inversion recovery hyperintense regions (FLAIR ROI ) were segmented. FDOPA hypermetabolic regions (FDOPA ROI , tumor-to-striatum ratios > 1) within FLAIR ROI were extracted. Normalized maximum standardized uptake value (nSUV max ), volume of each ROI, and median relative cerebral blood volume (rCBV) and apparent diffusion coefficient (ADC) within FLAIR ROI or FDOPA ROI were calculated. Imaging metrics were compared using Students t or Mann–Whitney U tests. Area under the curve (AUC) of receiver-operating characteristic curves were used to determine whether imaging metrics within FLAIR ROI or FDOPA ROI can discriminate different molecular statuses or grades. Results Using either FLAIR ROI or FDOPA ROI , the nSUV max and rCBV were significantly higher and the ADC was lower in isocitrate dehydrogenase (IDH) wild-type than mutant gliomas, and in higher-grade gliomas (HGGs) than lower-grade gliomas (LGGs). The FDOPA ROI volume was significantly higher in 1p19q codeleted than non-codeleted gliomas, and in HGGs than LGGs. Although not significant, imaging metrics extracted by FDOPA ROI discriminated molecular status and tumor grade more accurately than those extracted by FLAIR ROI (AUC of IDH status, 0.87 vs. 0.82; 1p19q status, 0.78 vs. 0.73; grade, 0.87 vs. 0.76). Conclusion FDOPA hypermetabolic ROI may extract useful imaging features of gliomas, which can illuminate biological differences between different molecular status or tumor grades.